The preliminary results showed that a single intradermal injection of the NF-κB tolDCs was safe and that immunoregulatory and anti-inflammatory effects were observed in HLA risk genotype-positive RA patients. The gene discussed is NFKB1; the disease is rheumatoid arthritis.